The paper traces the evolution of Oseltamivir (Tamiflu) synthesis, from Gilead’s initial methods in the 1990s to Roche’s current industrial route. Early challenges included raw material shortages and safety risks with azide intermediates. Roche’s 12-step method, still the most widely used, has faced issues with scalability and safety. Over time, alternative azide-free and non-shikimic acid […]
Author Archives: truemeds
Artificial Intelligence (AI) is transforming drug discovery by accelerating the prediction of drug activity, optimizing molecular designs, and personalizing treatments. This blog examines how AI technologies, such as machine learning and neural networks, are applied to predict drug-target interactions, efficacy, and toxicity. While AI offers significant advantages, such as reducing the time and cost of […]
Cariprazine, an atypical antipsychotic, has emerged as a promising adjunctive therapy for patients with Major Depressive Disorder (MDD), particularly those with treatment-resistant depression (TRD). Its unique pharmacological profile, including partial agonism at dopamine D2 and D3 receptors, distinguishes it from other antidepressant treatments. Clinical trials have demonstrated its efficacy in alleviating symptoms such as anhedonia, […]
10
Jun
Jun
The rising global prevalence of metabolic dysfunction-associated steatohepatitis (MASH) has highlighted the need for effective and economically viable treatments. Resmetirom, the first FDA-approved drug for MASH, offers a promising therapeutic option with its ability to reduce liver fat, improve liver function, and slow disease progression. This article discusses the economic considerations surrounding resmetirom’s potential cost-effectiveness, […]
Epidermal Growth Factor (EGF) plays a crucial role in the construction and maintenance of organoid models, which are three-dimensional in vitro structures mimicking human organs. EGF supports key processes in organoid development, including cell proliferation, stem cell renewal, differentiation, and morphogenesis. This growth factor is integral to maintaining the structural integrity and functionality of organoids, […]
Laduviglusib, a potent GSK3β inhibitor, has emerged as a promising therapeutic agent for a variety of diseases, including neurodegenerative disorders, cancer, and metabolic diseases. By targeting GSK3β, an enzyme critical for numerous biological processes such as cell survival, metabolism, and apoptosis, Laduviglusib modulates key pathways involved in the progression of these conditions. Clinical trials have […]
Resmetirom: Metabolic dysfunction-associated steatohepatitis (MASH) represents a growing public health concern due to its association with obesity, type 2 diabetes, and metabolic dysfunction. The recent FDA approval of Resmetirom (MGL-3196) marks a significant milestone in MASH treatment. Resmetirom is a thyroid hormone receptor beta (THR-β) agonist that targets the liver to reduce hepatic fat accumulation, […]
Prostaglandin D2 (PGD2) and its receptors, particularly DP2 (CRTH2), play a crucial role in mediating eosinophilic inflammation, which is central to the pathophysiology of various allergic and eosinophil-driven diseases, including asthma, allergic rhinitis, and atopic dermatitis. Targeting PGD2 signaling through receptor antagonists and inhibitors of PGD2 synthesis has shown promise in preclinical and clinical studies, […]
AOD-9604 is a synthetic peptide derived from the 177–191 amino acid sequence of human growth hormone (hGH). This fragment is designed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without elevating IGF-1 or affecting glucose metabolism. Its unique action may support localized fat loss, metabolic regulation, and joint recovery, making it a promising […]
Aprocitentan: Resistant hypertension remains a significant global health challenge, affecting patients who fail to achieve blood pressure control despite using multiple antihypertensive medications. Aprocitentan, a dual endothelin receptor antagonist (ERA), is emerging as a promising treatment by targeting ETA and ETB receptors, reducing vasoconstriction and inflammation. Recent clinical trials, including the PRECISION Phase III study, indicate that Aprocitentan […]